Regardless, our results suggest that the combination of mutant BRAF inhibitors and HSP90 inhibitors is a useful strategy to improve their therapeutic efficacy in the treatment of mutant BRAF colon cancer. This evidence concerns the gene BRAF and colonic neoplasm.